Lilly
Biotech

Lilly’s $2.3B Ajax drug works ‘right out of the gate’

The early data showed the novel JAK2 inhibitor “started working right out of the gate, with a good safety profile,” Lilly’s Jake Van Naarden said.
Angus Liu Jun 13, 2026 11:15am
Bull market

Biotech IPOs here to stay after another record-breaking listing

Jun 12, 2026 11:00am
How NECs AI and oral delivery system are redefining personalized cancer therapy

How NEC's AI and oral delivery system are redefining personalized cancer therapy

Brought to you by NEC Bio
Closeup of blue eye on black background

J&J channels $1B toward Acuvue lens facility expansion

Jun 15, 2026 11:28am
Eclipse

Intellia touts ‘paradigm shifting’ HAE data

Jun 15, 2026 10:37am
Law Legal System Justice Crime concept Mallet Gavel Hammer and Scales on tabl

Amgen loses in Harbour antibody patent case, ordered to pay $20M+

Jun 15, 2026 10:34am
More News

Neumora's navacaprant strikes out in phase 3 depression studies

Jun 15, 2026 10:16am

Fierce Biotech Layoff Tracker 2026: Genentech, Fulcrum & more

Jun 15, 2026 10:00am

Traws defers midphase flu study after negative regulatory review

Jun 15, 2026 9:19am

Soligenix axes lymphoma program after phase 3 setback

Jun 15, 2026 7:53am